BRIEF-Australia's ACCC Says Zoetis' Acquisition Of Neogen Genomics Requires Phase 2 Review

Zoetis, Inc. Class A
Neogen Corp

Zoetis, Inc. Class A

ZTS

0.00

Neogen Corp

NEOG

0.00

July 17 (Reuters) - Australia's ACCC:

  • ZOETIS’ ACQUISITION OF NEOGEN GENOMICS REQUIRES PHASE 2 REVIEW

  • ALSO CONSIDERING COMPETITIVE SIGNIFICANCE OF ZOETIS OBTAINING ACCESS TO INCREASED VOLUME OF GENETIC DATA ON CATTLE IN AUSTRALIA UNDER DEAL

  • NOT REACHED CONCLUSION ON ISSUES, WILL CONTINUE TO CONSIDER ACQUISITION OF NEOGEN IN PHASE 2

  • INVITES SUBMISSIONS IN RESPONSE TO ITS PHASE 2 NOTICE BY 31 JULY ON ZOETIS’ ACQUISITION OF NEOGEN

Further company coverage: ZTS.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.